Every step shouldn’t feel like a battle, yet for millions of people living with knee osteoarthritis, that painful reality is all too familiar. The gradual breakdown of cartilage within the knee joint creates a cascade of symptoms including stiffness, swelling, and persistent pain that can significantly diminish your quality of life. The good news is that osteoarthritis knee joint treatment has evolved dramatically, offering patients a wide spectrum of options ranging from conservative lifestyle modifications to advanced surgical interventions.
Understanding which treatment path is right for you requires more than a basic overview. It demands a clear-eyed analysis of the evidence behind each approach, the realistic outcomes you can expect, and the factors that influence clinical decision-making. This guide is designed to deliver exactly that.
Whether you are newly diagnosed, reassessing a current treatment plan, or exploring options your doctor has recommended, this comprehensive breakdown will walk you through the full landscape of available therapies. You will leave with a sharper understanding of how each option works, who it benefits most, and how to have more informed conversations with your healthcare provider.
What Is Knee Osteoarthritis and Why Does It Progress?
Knee osteoarthritis is a complex degenerative joint condition characterised by the progressive breakdown of articular cartilage, the smooth tissue covering the ends of bones within the joint. It is frequently — and inaccurately — dismissed as simple “wear and tear” associated with ageing. In reality, the Osteoarthritis Research Society International defines OA as a disorder involving cell stress and extracellular matrix degradation, initiated by micro- and macro-injury that activates maladaptive repair responses, including pro-inflammatory pathways of innate immunity. Understanding this distinction matters clinically, because it reframes OA as a targetable biological process rather than an inevitable consequence of getting older.
Central to joint health is the role of synovial fluid, which lubricates movement, delivers nutrients to cartilage, and protects against harmful substances entering the joint space. Hyaluronic acid (HA) is a key structural component of this fluid, providing viscosity, shock-absorbing capacity, and a filtration barrier for damaging molecules. As OA develops and progresses, HA concentration within the synovial fluid declines significantly. The result is reduced lubrication, increased inter-surface friction, and an accelerating cycle of cartilage loss that becomes increasingly difficult to reverse without intervention.
The disease process does not stop at mechanical deterioration. Cartilage debris and degradation byproducts stimulate the synovial lining, triggering an inflammatory response that elevates pro-inflammatory cytokines including IL-1β and TNF-α. This synovial inflammation is now recognised as a central driver of OA progression rather than a secondary effect, creating a self-perpetuating cycle of structural damage that extends to bone remodelling, osteophyte formation, and joint capsule thickening.
Risk factors for knee OA span both modifiable and non-modifiable categories. Advancing age, elevated BMI, previous joint injury, repetitive occupational loading, and high-impact activity history all contribute to disease onset and progression. Within a sports medicine population, post-traumatic OA is particularly relevant; a history of ACL rupture, meniscal injury, or significant joint trauma meaningfully increases long-term OA risk, even in younger patients.
Knee OA is among the most common causes of knee pain, stiffness, and reduced mobility in middle-aged and older adults, but clinicians are increasingly identifying it in younger, active individuals following joint injury. Symptoms typically include gradual-onset pain worsening with activity, morning stiffness, and swelling, though it is important to note that symptom severity does not always correlate with the degree of structural damage visible on imaging.
How OA Severity Guides Your Treatment Pathway
Not all knee osteoarthritis is equal, and one of the most important tools clinicians use to distinguish severity is the Kellgren-Lawrence (KL) grading system. This radiographic classification framework runs from Grade 1 to Grade 4, mapping the progressive structural deterioration of the joint. Grade 1 reflects early, doubtful joint space narrowing with possible osteophyte formation; Grade 2 shows definite osteophytes with possible narrowing; Grade 3 demonstrates moderate osteophytes, definite joint space narrowing, and early sclerosis; Grade 4 represents severe bone-on-bone change with marked deformity. Understanding where a patient sits on this scale is foundational to designing an appropriate, evidence-based treatment pathway.
Matching Treatment to Disease Stage
At Grades 1 and 2, the priority is intervention that can genuinely influence the disease trajectory rather than simply suppress symptoms. Supervised exercise rehabilitation and physiotherapy form the cornerstone of care at this stage, with strong support from the AAOS 2021 Clinical Practice Guideline for knee osteoarthritis. Biologic injection therapies, including viscosupplementation with hyaluronic acid and platelet-rich plasma, are well-suited to early-stage disease, where the cartilage environment is still sufficiently intact to respond to these interventions.
At Grades 2 and 3, combination strategies become more clinically relevant. Pairing structured physiotherapy with targeted injection therapy, whether PRP, hyaluronic acid, or corticosteroids for acute inflammatory flares, addresses both the mechanical and biological dimensions of the condition. As severity increases toward Grades 3 and 4, options such as Arthrosamid, a polyacrylamide hydrogel injection offering longer-duration intra-articular effect, and corticosteroid therapy play a greater role in symptom management. At Grade 4, non-operative management should be fully optimised before surgical referral discussion, including the possibility of total knee arthroplasty.
Why One Approach Does Not Fit Every Patient
KL grade alone does not dictate treatment. A 45-year-old recreational runner with Grade 2 changes and high activity goals requires a very different clinical conversation than a 70-year-old with Grade 2 changes, cardiovascular comorbidities, and limited functional demands. Age, body weight, rate of disease progression, and individual rehabilitation capacity all shape which therapies are appropriate and in what sequence. At Pro Sports Medicine, our multidisciplinary team, including sports medicine doctors, physiotherapists, and orthopaedic consultants, reviews these factors collectively to build truly personalised treatment plans.
The Cost of Waiting
Perhaps the most clinically significant mistake patients make is delaying assessment and treatment until symptoms become severe. By the time pain becomes debilitating, Grade 3 or 4 structural changes may already be present, and the window for disease-modifying intervention has narrowed considerably. The opportunity to slow cartilage degeneration, preserve joint mechanics, and avoid or defer surgery is greatest at Grades 1 and 2. Early assessment is not about over-medicalising mild symptoms; it is about accessing the right treatments at the point when they can make the most meaningful difference to long-term joint health.
The Role of Diagnosis and Imaging in Treatment Decisions
Knowing a patient has knee osteoarthritis is only the starting point. Understanding precisely what structural changes are present, and which tissues are affected, is what determines the right treatment. Clinical examination alone cannot reliably distinguish between a knee driven primarily by synovial inflammation and one where cartilage loss is the dominant pathology. It also cannot rule out co-existing conditions such as meniscal tears or ligament damage, both of which significantly alter the treatment approach. Two patients can present with identical pain scores and identical Kellgren-Lawrence grades on X-ray, yet have completely different underlying structural profiles requiring very different clinical responses.
Diagnostic Ultrasound: Real-Time Structural Insight
Diagnostic ultrasound has become an essential first-line imaging tool in musculoskeletal and sports medicine practice. As a dynamic, real-time modality, it allows clinicians to assess joint effusion, grade synovitis through Power Doppler imaging, visualise cartilage surface changes along the femoral condyle, and identify osteophyte formation at joint margins. A 2026 study published in The Scientific World Journal confirmed that ultrasound-based severity parameters correlate meaningfully with Kellgren-Lawrence grading while providing additional structural detail beyond what plain radiography can offer. Critically, ultrasound-guided injection placement improves the accuracy with which therapeutic agents, whether hyaluronic acid, PRP, or corticosteroid, are delivered into the joint space, directly improving treatment outcomes.
MRI: Comprehensive Soft Tissue and Cartilage Evaluation
Where ultrasound provides real-time surface-level assessment, MRI remains the gold standard for comprehensive structural evaluation. It allows detailed characterisation of cartilage integrity, subchondral bone marrow lesions, meniscal tears, ligament status, and synovial thickening simultaneously. Importantly, recent advances in MRI-based analysis are moving clinical research beyond pain scores as sole outcome measures, with structural endpoints now increasingly central to evaluating treatment effectiveness. This shift matters clinically: a Grade 2 knee with significant active synovitis may respond better to an anti-inflammatory injection protocol, while a Grade 2 knee presenting with cartilage thinning and minimal inflammation may be better served by viscosupplementation or a chondroprotective PRP approach.
At Pro Sports Medicine, both diagnostic ultrasound and access to MRI services are integral to how treatment plans are built. Rather than relying on symptoms alone, objective structural findings guide every recommendation, ensuring patients receive precisely targeted care rather than a generic pathway.
Physiotherapy and Exercise Rehabilitation
Physiotherapy is not a secondary option to consider once other treatments have been exhausted. It is the evidence-based, guideline-endorsed first-line treatment for knee osteoarthritis across all severity grades, from early-stage KL Grade I changes through to more advanced structural degeneration. A 2025 narrative review in the European Journal of Medical Research frames an integrated rehabilitation framework combining exercise, biomechanical correction, and physiotherapist guidance as best practice throughout the OA spectrum. This distinction matters clinically: physiotherapy addresses the underlying mechanical drivers of joint degeneration that no injection can resolve in isolation.
The mechanisms are well established. Quadriceps weakness is a recognised and modifiable risk factor in knee OA; it disrupts force distribution across the joint during weight-bearing and increases compressive load on the medial compartment, the most commonly affected region. Targeted quadriceps strengthening directly counteracts this. Equally important is hip abductor training, which corrects frontal-plane mechanics and reduces the knee adduction moment, a key driver of medial compartment loading. Neuromuscular training adds a further dimension by restoring joint proprioception and dynamic stability, particularly valuable in mechanically compromised knees where passive structures are less reliable. A 2025 systematic review by Hegde et al. confirmed that quadriceps strengthening, alone or combined with hip abductor work, produced significant improvements in both pain and function across all included randomised controlled trials.
A specialist knee OA rehabilitation programme at Pro Sports Medicine is structured to address each of these factors systematically. It typically incorporates load management in the early phase, progressive resistance training at 60 to 80 percent of one repetition maximum, gait retraining to modify loading patterns, activity modification to protect the joint during recovery, and clearly defined return-to-function goals across daily activities, work demands, and sport where relevant. Supervised programmes consistently outperform unsupervised approaches, with research showing meaningfully greater effect sizes for both pain and functional outcomes when physiotherapist-guided sessions exceed twelve in number.
Crucially, physiotherapy and injection therapies are complementary, not competing. Injections reduce pain and inflammation, creating a window in which rehabilitation becomes more tolerable and effective. Physiotherapy then addresses the biomechanical factors that drive continued OA progression, enhancing and prolonging the clinical benefit of the injection. This integrated approach is central to how the physiotherapy team at Pro Sports Medicine works alongside our sports medicine doctors; rehabilitation is coordinated with clinical treatment rather than delivered in isolation, ensuring patients benefit from both the symptom relief of injection therapy and the structural protection of a structured exercise programme.
Corticosteroid Injections: Rapid Relief With a Role in the Pathway
Corticosteroids are among the most potent anti-inflammatory agents used in musculoskeletal medicine, and their mechanism is well understood. When injected directly into the knee joint, they suppress the local inflammatory cascade, inhibiting the pro-inflammatory mediators responsible for synovial inflammation, pain, and swelling. The effect is rapid, typically producing meaningful symptom relief within days, which distinguishes them from other intra-articular options that act over a longer timeframe. A meta-analysis published in the BMJ confirmed the short-term efficacy of corticosteroid injections for knee OA, reporting a pooled relative risk for symptom improvement at two weeks of 1.66, and a number needed to treat of just 4.4 in high-quality studies. These are clinically significant figures that reflect genuine, measurable benefit.
Patient selection matters considerably. The strongest candidates are those presenting with active synovitis, visible joint effusion, or pain severe enough to prevent meaningful engagement with physiotherapy or rehabilitation. In these cases, attempting to push through exercise-based treatment without first addressing the inflammatory environment is often counterproductive. A well-timed corticosteroid injection can break that cycle, reduce the inflammatory burden, and create a clinical window within which rehabilitation can begin effectively.
That said, the limitations deserve equal weight. Effect duration is typically in the range of six to twelve weeks, and repeated high-frequency administration carries genuine risks, including adverse effects on cartilage integrity and local tissue changes such as tendon weakening. This makes corticosteroids poorly suited as a long-term standalone strategy. Current clinical consensus suggests limiting injections to no more than three or four per year, with each decision made based on individual clinical presentation.
Their real value lies in sequencing. A corticosteroid injection to rapidly control acute inflammation, followed by structured physiotherapy or viscosupplementation, is a clinically rational and widely applied pathway. Contemporary orthopaedic literature, including a 2026 review in Orthopedic Reviews, recognises combination strategies such as hyaluronic acid with corticosteroids among evidence-based directions for knee OA management, reflecting a shift toward multimodal, sequenced treatment rather than single-intervention thinking. At Pro Sports Medicine, our clinicians assess each presentation individually to determine whether corticosteroids form the right starting point within a personalised treatment plan.
Hyaluronic Acid Injections (Viscosupplementation)
In healthy synovial fluid, hyaluronic acid functions as the joint’s natural lubricant and shock absorber, creating the viscous, gel-like environment that allows cartilage surfaces to glide smoothly under load. A single gram of HA can bind up to six litres of water, which illustrates just how critical this molecule is to normal joint mechanics. As knee osteoarthritis progresses, both the concentration and molecular weight of naturally occurring HA in synovial fluid deteriorate significantly. The result is a thinner, less elastic fluid that provides inadequate cushioning and lubrication, accelerating the cycle of friction, inflammation, and cartilage breakdown that defines the condition.
Intra-articular HA injections, commonly referred to as viscosupplementation, address this deterioration through two complementary mechanisms. The first is mechanical: injected HA replenishes the viscoelastic properties of synovial fluid, restoring its capacity to lubricate joint surfaces and absorb compressive forces during movement. The second is biological: HA exerts a secondary anti-inflammatory and chondroprotective effect on the synovial membrane, helping to dampen the inflammatory environment that perpetuates tissue damage. This dual mechanism is precisely why HA is positioned differently in the treatment pathway compared to corticosteroids, which act purely through immune suppression.
Patient selection is central to achieving good outcomes. Viscosupplementation is most effective in mild-to-moderate knee OA, broadly corresponding to Kellgren-Lawrence Grades 1 to 3, where patients have not achieved sufficient relief from physiotherapy and analgesics alone. At Grade 4, where bone-on-bone contact is present and joint space is severely compromised, the mechanical rationale for viscosupplementation is substantially reduced, and surgical options become more relevant.
Treatment protocols vary according to product formulation, ranging from a single high-molecular-weight injection to a course of three to five injections administered weekly. Symptom relief typically lasts between three and six months, and some high-molecular-weight preparations have demonstrated durability beyond this window in clinical practice. The 2026 evidence-based review published in Orthopedic Reviews by Cao, Tang, and Tran confirms HA monotherapy as a well-established and clinically validated approach, drawing on a comprehensive search across PubMed, Embase, the Cochrane Library, and Web of Science. For patients seeking a non-steroidal, minimally invasive option that addresses both the mechanical and inflammatory dimensions of knee OA, viscosupplementation represents a clinically sound and evidence-supported choice within a structured management pathway.
PRP Injections: The Evidence, the Potential, and the Honest Picture
Platelet-rich plasma therapy occupies a genuinely interesting position in the osteoarthritis treatment landscape, because the biology underpinning it is both compelling and increasingly well-supported by clinical data. The process begins with a small blood draw from the patient, which is then centrifuged to concentrate the platelet fraction significantly above baseline levels. Those concentrated platelets release a cascade of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), that activate the joint’s natural repair mechanisms. Critically, this process also works to reduce key inflammatory mediators, specifically interleukin-1 beta (IL-1β) and tumour necrosis factor-alpha (TNF-α), both of which drive cartilage breakdown and pain in osteoarthritic joints. Because PRP is autologous, meaning derived entirely from the patient’s own blood, systemic immune reactions are extremely rare, which distinguishes it favourably from pharmacological alternatives.
The clinical evidence comparing PRP directly against hyaluronic acid has matured considerably. A 2023 systematic review and meta-analysis by Li et al., examining 14 randomised controlled trials, found that PRP produced significantly lower VAS pain scores than HA at both the three-month and twelve-month follow-up points. Functional outcomes told a similar story, with PRP demonstrating superior WOMAC scores at one, three, six, and twelve months across the pooled data. For patients who have not achieved adequate or sustained relief from HA alone, this meta-analysis published on PubMed positions PRP as a credible next step offering longer-duration benefit rather than simply an alternative with equivalent results.
The question of whether PRP might do more than manage symptoms, specifically whether it can slow cartilage degeneration in early-stage OA, is where the science becomes more nuanced and honesty is important. Some research suggests a potential structure-modifying effect, and this possibility is partly what drives clinical enthusiasm. However, the American Orthopaedic Society for Sports Medicine’s 2024 position is measured; the data is considered encouraging, but the evidence does not yet meet the threshold required for definitive disease-modifying claims. This remains an active area of investigation rather than settled science, and any clinician presenting PRP as a confirmed cartilage-regenerating therapy is overstating the current evidence base.
On safety, the Li et al. 2023 meta-analysis found no significant difference in overall complication rates between PRP and HA, which is a reassuring finding. PRP was associated with higher rates of temporary local injection-site pain, a transient inflammatory response that typically resolves within a few days and does not reflect a serious adverse event. No significant systemic complications were reported across the analysed trials.
In terms of patient selection, the evidence is clearest for those with early-to-moderate disease, specifically Kellgren-Lawrence Grade 1 to 3. Patients seeking outcomes that extend meaningfully beyond the typical corticosteroid window, or those who have trialled HA without sufficient benefit, represent the strongest candidates. At Pro Sports Medicine, PRP injections are delivered under ultrasound guidance to optimise placement precision, as part of an individually tailored treatment plan that considers each patient’s OA severity, functional goals, and treatment history.
Combination Therapy: When HA and PRP Work Together
The logic behind combining hyaluronic acid and PRP is not a matter of doing more for the sake of it. It is rooted in the fact that each agent targets a genuinely different biological problem within the osteoarthritic joint. HA works as a viscosupplement, restoring the mechanical and rheological properties of synovial fluid that progressively deteriorate as OA advances. PRP, by contrast, delivers a concentrated payload of growth factors including PDGF, TGF-β, and VEGF, alongside anti-inflammatory cytokine signalling that targets the molecular drivers of cartilage degradation. Because these mechanisms operate on distinct but interconnected pathways, combining them is additive rather than duplicative. One addresses the mechanical environment of the joint; the other addresses the biological one. That is a meaningful clinical distinction, not a subtle one.
The evidence base is now beginning to reflect this rationale at a meaningful level. A 2026 evidence-based review published in Orthopedic Reviews identifies HA plus PRP and HA plus corticosteroids as the leading combination strategies in current knee OA injection management, representing a broader shift away from uniform single-agent protocols toward personalised, multi-mechanism approaches. This is not fringe thinking; it reflects where the most current systematic evidence is pointing. Reinforcing this, a 2025 randomised controlled trial published in the Journal of Clinical Medicine compared PRP plus HA combination therapy against HA alone and introduced a significant methodological advance: MRI analysis as a structural outcome measure. Where earlier studies relied primarily on patient-reported pain scores and functional questionnaires such as WOMAC and VAS, this trial introduced the capacity to detect changes in cartilage volume and synovial status, outcomes relevant to disease modification rather than symptom relief alone.
In terms of patient selection, two profiles emerge most clearly from the current evidence. Patients with mild-to-moderate OA, broadly corresponding to Kellgren-Lawrence Grade II to III, retain sufficient cartilage matrix to respond to biological stimulation from PRP, while also experiencing measurable deterioration in synovial fluid mechanics that HA can address. The second group are partial responders; patients who achieved some, but incomplete, relief from either HA or PRP as a standalone treatment. Their partial response suggests residual biological or mechanical capacity, but that a single dimension of treatment was not sufficient on its own.
At Pro Sports Medicine, combination injection therapy is available as part of an individually structured, evidence-informed treatment protocol. The decision to combine agents is made following thorough clinical assessment, relevant imaging, and consideration of a patient’s full treatment history. This is not a standardised escalation applied uniformly; it is a clinician-led judgment based on where a specific patient sits within their OA journey and what their joint is likely to respond to at that stage.
Arthrosamid and KioMedine: Longer-Duration Options Explained
Not all injectable treatments for knee osteoarthritis work through the same biological pathway, and understanding these differences is what separates a well-matched treatment plan from an average one. Arthrosamid represents a genuinely distinct category within the injectable landscape. Rather than supplementing synovial fluid or delivering growth factors, it is a 2.5% cross-linked polyacrylamide hydrogel, comprising 2.5% polyacrylamide and 97.5% non-pyrogenic water. Critically, it is non-biodegradable and non-absorbable, meaning it is not broken down or cleared by the body over time. Instead of simply occupying the joint space temporarily, Arthrosamid integrates directly into the synovial membrane tissue, mechanically softening it and restoring elasticity. This structural integration is what differentiates it fundamentally from both hyaluronic acid and PRP.
The clinical significance of this mechanism is considerable. Because Arthrosamid is not metabolised, it does not require repeated injection cycles in the way that HA viscosupplementation does. Standard HA injections typically require courses of multiple injections, and evidence suggests their benefit can diminish within six months for many patients. Arthrosamid, by contrast, is administered as a single ultrasound-guided intra-articular injection of 6ml, designed to provide sustained pain relief over a significantly longer period. For patients who have found HA helpful but experienced a return of symptoms requiring further courses, or for whom repeated clinic visits are impractical, this difference in durability carries real clinical and practical weight.
KioMedine is an advanced viscosupplementation option that sits alongside these injectables within a personalised treatment pathway. It offers characteristics suited to specific patient profiles where conventional HA products may not be the optimal choice, and our clinical team will discuss where it fits most appropriately during your assessment.
The patient profile most suited to these longer-duration injectables tends to be those with moderate osteoarthritis, typically Kellgren-Lawrence grade two to three, who have responded positively to HA in the past but experienced short-lived benefit, and who are not yet appropriate candidates for surgical intervention. Patients who find repeated injection schedules difficult to manage, whether for practical or personal reasons, are also well-suited candidates for consideration.
Both Arthrosamid and KioMedine are specialist treatments. Suitability requires thorough clinical assessment, including imaging review and a detailed history of prior treatments. At Pro Sports Medicine, our sports medicine doctors deliver these injections under ultrasound guidance, ensuring accurate placement and appropriate patient selection at every stage.
Comparing Your Options: A Framework for Decision-Making
Having explored each treatment in detail across previous sections, it is worth bringing everything together into a practical reference framework. The reality of osteoarthritis knee joint treatment is that no single intervention is universally superior, and the evidence consistently supports personalised, sequenced decision-making rather than a one-size-fits-all approach.
The table below provides a structured overview of the key treatment modalities, mapped against OA grade suitability, primary mechanism, and expected duration of benefit:
| Treatment | Best-Suited OA Grade | Primary Role | Expected Duration |
|---|---|---|---|
| Physiotherapy | All grades (foundational) | Strength, function, load management | Ongoing with adherence |
| Corticosteroid injection | Grade 2-4 (acute flare) | Rapid anti-inflammatory relief | Weeks to 3 months |
| Hyaluronic acid (HA) | Grade 1-3 | Viscosupplementation, lubrication | 3-6 months |
| PRP | Grade 1-3 | Biological repair stimulus | 6-12+ months |
| HA + PRP combination | Grade 2-3 | Dual mechanical and biological mechanism | Extended, typically beyond single agent |
| Arthrosamid | Grade 2-3 | Long-duration joint cushioning | Long-duration, potentially years |
| Surgical referral | Grade 3-4 (treatment-refractory) | Structural correction | Long-term post-operative |
No single treatment wins across every patient. The 2023 Li et al. meta-analysis, which reviewed 14 randomised controlled trials, demonstrated that PRP produced significantly better VAS pain scores than HA at both 3 and 12 months, with superior WOMAC functional scores at 1, 3, 6, and 12 months. That is a meaningful result, but it does not mean PRP is the correct first choice for every patient. OA grade, degree of active inflammation, previous treatment history, and individual health factors all influence which approach is most appropriate at any given point in time.
Multimodal treatment consistently produces more durable outcomes than any single intervention delivered in isolation. Combining physiotherapy with an appropriately matched injection therapy addresses both the structural environment of the joint and the neuromuscular deficits that drive abnormal loading. This combination produces better long-term results because it targets the condition on multiple levels simultaneously.
Treatment sequencing is a clinical discipline in itself. The standard approach at a specialist sports medicine centre is to begin with the least invasive appropriate option and escalate based on clinical response. This is not a passive or hesitant strategy; it is a systematic method that ensures each treatment is given a genuine opportunity to work before introducing greater complexity. At Pro Sports Medicine in Cardiff, that sequencing decision is made by clinicians who have assessed and managed knee OA to the standard demanded in professional sport, bringing the same rigour to every patient who walks through the door.
Cost, Access, and What to Expect as a UK Patient
For most patients in the UK, the journey with knee osteoarthritis begins through the NHS, and that pathway has genuine value. A GP assessment, analgesia, and a physiotherapy referral form a clinically appropriate starting point, and NICE guidelines (NG226) support this conservative-first approach. Corticosteroid injections are also available through NHS services in appropriate cases. However, access to PRP, hyaluronic acid viscosupplementation, Arthrosamid, and combination injection protocols is not routinely available on the NHS. These treatments sit firmly within the specialist private sector, and for patients with moderate OA who are not yet candidates for surgery but are struggling with pain and function, this distinction matters considerably.
It also matters in terms of timing. In Wales and across the UK, waiting times for orthopaedic assessment and physiotherapy can extend to many months. Given that osteoarthritis is a progressive, degenerative condition, a prolonged wait is not simply an inconvenience; it is a period during which joint degeneration can continue unchecked. Accessing specialist private care earlier is therefore a clinically relevant decision, not merely a lifestyle preference.
On the question of cost, transparency is important. Corticosteroid injections represent the most accessible price point. Hyaluronic acid viscosupplementation typically involves one to three sessions and is priced accordingly. PRP carries a higher cost per session, reflecting the preparation process involved: blood is drawn, centrifuged, and processed to concentrate the platelet fraction before injection. Arthrosamid, as a single-procedure polyacrylamide hydrogel treatment designed for longer-duration benefit, represents a premium investment upfront but may be more cost-effective than repeated injection cycles over time. The right option depends on clinical stage, patient goals, and individual circumstances, which is why cost should always be discussed in the context of a full assessment rather than in isolation.
At Pro Sports Medicine in Cardiff, patients across South Wales and beyond have access to a multidisciplinary specialist team under one roof. A Sports Medicine Doctor assessment, combined with point-of-care diagnostic ultrasound and the full range of injection therapies, represents a fundamentally different level of care than a standard GP referral. It is precise, personalised, and built around getting the right treatment to the right patient at the right time.
When Surgery Becomes the Right Conversation
Surgery for knee osteoarthritis, whether total or partial knee replacement, sits firmly at the end of the treatment pathway. It is not a first-line option, and current clinical guidelines from both the ACR and AAOS are explicit on this point: surgical assessment becomes appropriate only after conservative therapies, rehabilitation, and injection-based treatments have been genuinely exhausted and have failed to restore adequate function and quality of life.
Several clinical indicators, when they converge, shift the conversation meaningfully toward surgical assessment. Radiographic evidence of Kellgren-Lawrence Grade 4 OA, characterised by severe joint space narrowing, large osteophytes, subchondral sclerosis, and bone-on-bone change, forms an important part of the picture. Alongside this, persistent severe pain that remains uncontrolled despite optimised non-surgical management, significant functional limitation affecting everyday activities, and documented failure across multiple injection modalities, including corticosteroid, hyaluronic acid, and PRP protocols, collectively indicate that the joint has reached a threshold where surgical assessment is clinically warranted. Crucially, radiographic grade alone is insufficient; functional status, pain severity, and quality of life must all be considered together.
This is where specialist sports medicine assessment adds genuine clinical value. Not every patient who appears to be approaching a surgical threshold has truly exhausted their non-surgical options. Advanced combination injection protocols, targeted rehabilitation, and newer longer-acting injectables may still provide meaningful benefit for the right candidate. A thorough specialist evaluation can identify whether that window remains open, preventing premature escalation into a surgical pathway before it is truly necessary.
At Pro Sports Medicine, when surgical assessment does become appropriate, patients benefit from established relationships with leading orthopaedic surgeons across South Wales. Referrals are coordinated and well-documented, ensuring continuity of care rather than a fragmented handover. Furthermore, optimising joint health through rehabilitation and appropriate injection therapy before surgery, where timing allows, is supported by evidence demonstrating improved surgical safety and recovery trajectories in patients who enter the operating room in better functional condition.
Why Specialist Assessment Changes Treatment Outcomes
The breadth of treatment options now available for knee osteoarthritis is genuinely significant. From structured physiotherapy and corticosteroid injections through to hyaluronic acid viscosupplementation, PRP, Arthrosamid, and evidence-informed combination protocols, the range of interventions has expanded considerably. This is, on balance, a positive development for patients. But it also raises an important clinical reality: the quality of your initial assessment directly determines the quality of your treatment plan. Choosing between HA monotherapy and a PRP plus HA combination protocol, for example, is a consequential clinical decision. It cannot be made well without a thorough understanding of disease severity, structural status, activity demands, and prior treatment history. Getting that first step right is everything.
At Pro Sports Medicine in Cardiff, the assessment model is built around exactly this principle. The clinic brings together Sports Medicine Doctors, Physiotherapists, Orthopaedic Consultants, a Consultant Radiologist, Podiatrists, and Soft Tissue Therapists within a single, coordinated team. Each specialist contributes a distinct clinical lens. A Podiatrist, for instance, can identify lower limb biomechanical factors that may be accelerating joint loading and OA progression, an insight that would simply not emerge from a single-discipline consultation. This multidisciplinary structure means patients are assessed as individuals, not presented with a default protocol.
This approach is grounded in the clinic’s founding principle, established in 2008: to deliver the same standard of care received by professional and elite athletes to every patient who walks through the door. In elite sport, a comprehensive specialist assessment is not a premium add-on. It is the baseline expectation, because the cost of an inaccurate or incomplete assessment is too high. That same standard applies here, regardless of whether a patient is a competitive athlete or someone managing daily pain on the stairs.
The diagnostic infrastructure reinforces this. In-house diagnostic ultrasound enables real-time structural assessment of soft tissue, synovitis, and effusion at the point of consultation. Combined with access to MRI, treatment decisions are guided by objective structural findings rather than assumptions drawn from symptoms alone. This matters more than ever given that recent research, including a 2025 RCT published in the Journal of Clinical Medicine, is now incorporating MRI as a primary structural outcome measure when evaluating combination injection therapies, confirming that imaging-guided assessment changes the quality of clinical conclusions.
If you are experiencing knee OA symptoms, wherever you are in your treatment journey, a specialist assessment provides three things: diagnostic clarity, an accurate picture of severity, and a complete view of all the options available to you. That is the most useful starting point, and it is available to you here.
Key Takeaways: Navigating Knee OA Treatment With Confidence
Knee osteoarthritis treatment is not a binary choice between managing pain with medication and waiting for surgery. A structured, evidence-based pathway combining physiotherapy, rehabilitation, injection therapies, and specialist-guided decision-making can significantly improve function and quality of life for the vast majority of patients. The key is understanding that each treatment serves a distinct purpose and that the right combination depends on OA grade, clinical findings, imaging, and your individual goals, not simply what is most familiar or most available.
Early intervention genuinely matters. The sooner knee OA is assessed and managed by a specialist, the greater the opportunity to slow progression, preserve joint integrity, and maintain the active life you want to lead. Waiting for symptoms to worsen before seeking help is one of the most common and most avoidable mistakes patients make.
At Pro Sports Medicine in Cardiff, our multidisciplinary team of sports medicine doctors, physiotherapists, orthopaedic consultants, and specialist radiologists delivers the full spectrum of evidence-based knee OA treatments under one roof. From physiotherapy and shockwave therapy to corticosteroid injections, hyaluronic acid viscosupplementation, PRP, Arthrosamid, and tailored combination protocols, every treatment decision is guided by clinical evidence and personalised assessment. If you are experiencing knee pain, stiffness, or reduced mobility, specialist assessment is the most important step you can take.
